Blog - Pharmaceutical Products

Merck Suspends Gardasil Shipments to China

Feb 4, 2025

Merck has temporarily halted Gardasil shipments to China due to reduced demand, impacting 2025 revenue forecasts, while Keytruda sales remain strong.

Pfizer Surpasses Earnings Expectations for Q4 and FY 2024

Feb 4, 2025

113

Pfizer surpasses Q4 and FY 2024 earnings expectations, with a strategic focus on cost reductions and revenue growth, overcoming challenges such as patent expirations and Medicare negotiations.

Merck's Earnings Align with Expectations, Stock Declines on 2025 Forecast

Feb 4, 2025

Merck's earnings aligned with Wall Street expectations, yet stocks fell due to a lackluster 2025 forecast. The company's reliance on products like Gardasil and Keytruda amid Chinese market challenges is under scrutiny.

Regeneron Pharmaceuticals Surpasses Quarterly Expectations and Announces Financial Initiatives

Feb 4, 2025

Regeneron Pharmaceuticals exceeds expectations with strong Dupixent sales, proposes dividend and share repurchase, maintaining a competitive edge despite challenges.

Novo Nordisk Faces Investor Scrutiny Over CagriSema Trials

Feb 4, 2025

Novo Nordisk faces investor pressure over CagriSema trials, as mixed results and side effects impact its market standing against competitors like Eli Lilly.

Germany's Antibiotic Imports Hit a Low of $303 Million in 2024

Feb 4, 2025

Antibiotic imports reached a peak of 3K tons in 2014, but from 2015 to 2024, they stayed at a lower level. In terms of value, antibiotic imports dropped to $303M in 2024.

Eli Lilly Prepares for Strong Earnings Report Amid High Analyst Expectations

Feb 3, 2025

123

Pharmaceutical giant Eli Lilly is poised for an impressive earnings report, powered by strong sales of its weight-loss drugs and a strategic market approach.

Experts Predict Smaller Winter COVID Wave in U.S., Impacting Pfizer's Growth

Feb 3, 2025

117

U.S. experts predict a smaller winter COVID wave, posing challenges for Pfizer amid declining revenues, emphasizing the need to diversify non-COVID products.

AstraZeneca Abandons £450m Vaccine Facility Development in the UK

Jan 31, 2025

103

AstraZeneca has abandoned plans for a £450m vaccine facility in the UK, highlighting economic and funding challenges. Learn about the implications for UK's life sciences sector.

AbbVie Projects Surpassing 2025 Profit Expectations with Immunology Drug Surge

Jan 31, 2025

143

AbbVie predicts exceeding 2025 profit expectations, bolstered by immunology drugs Skyrizi and Rinvoq, as Humira faces declining sales and rising competition.

Novo Nordisk Shares Surge After Successful Weight-Loss Drug Trial

Jan 31, 2025

513

Novo Nordisk experiences a share price surge after amycretin's promising weight-loss trial results, restoring investor confidence despite past setbacks.

China's Biotechnology Industry: A Rising Global Force

Jan 31, 2025

121

China's biotech industry is advancing with 4,804 drugs in development, leveraging licensing deals for potential revenue despite financial market challenges.